Ambrose Healthcare

Ilofotase alfa is a recombinant human alkaline phosphatase enzyme replacement therapy, engineered from two human isoforms of the enzyme to optimise stability and activity. It is in development for hypophosphatasia (HPP) and was acquired as part of Ambrose’s purchase of AM-Pharma.

Gastrointestinal symptoms in cystic fibrosis

QoL palliative care/cachexia in pancreatic cancer

The Structural Gap Between Discovery and Delivery

The paper shows how patient-focused methodologies, enabling technologies and emerging biopharma ecosystems will deliver a step change in the number of treatments needed for the estimated 400 million people living with a rare condition.

Ambrose Healthcare Ltd published a white paper on regulatory mechanisms that encourage rare disease treatment development, highlighting cost reduction and faster approvals.

Ambrose Healthcare shares news, whitepapers, and opinion pieces on its website.

Ambrose Healthcare appointed Dr Hazel Jones as Chief Operating Officer to lead operational strategy in rare disease therapeutics.

Ambrose Healthcare is delighted to announce the appointment of five exceptional senior leaders to its executive and operational team, marking a significant step forward in the company’s growth and strategic trajectory.

Ambrose Healthcare Ltd. is delighted to announce that it has won the Best Startup Biotech Company Award at the prestigious BioUK (formerly OBN) Awards 2024, held on 20 November in London.

Ambrose Healthcare Ltd (Ambrose Healthcare), an award-winning pharmaceutical company focused on driving change in rare diseases, reports that the option to acquire renzapride has been exercised, providing global ownership rights.

Having previously transformed a startup into a multi-million dollar pharmaceutical company, the Ambrose team is now focussing on sustainable access to life-changing drug treatments for rare disease patients.

Ambrose Healthcare is a pharmaceutical company focused on diagnosing rare diseases and delivering innovative treatments while balancing social and financial goals.

The page examines rare diseases, which affect over 400 million people worldwide, including regional definitions, global impact, and orphan drug history.

Ambrose Healthcare accelerates rare disease drug development by analyzing health records to identify undiagnosed patients and acquiring late-stage assets.

Ambrose Healthcare maintains a global network of rare disease experts and stakeholders to foster specialized discussions.

Ambrose Healthcare offers MagnetID services and collaborates on rare disease initiatives.

Ambrose Healthcare is an entrepreneurial pharma company working to drive change in rare diseases.